FDA data Registry peer set 3 peers FDA shortage listed

Alternatives to liraglutide

FDA shortage status is active for liraglutide; 3 same-class SPL records are listed below for registry comparison only.

Brand: Victoza, Saxenda

GLP-1 Receptor Agonist Prescription 3 alternatives found

liraglutide class peers while FDA lists an active shortage

liraglutide (Victoza, Saxenda) is on an FDA shortage listing while 3 other GLP-1 Receptor Agonist SPL records remain in this registry peer set (class inventory 4). Labeled indication field for liraglutide: Liraglutide helps manage blood sugar levels in people with type 2 diabetes.

Top FAERS reaction fields for liraglutide total 29,079 reports across 10 reactions, set beside dulaglutide, exenatide, semaglutide. Counts are exposure-weighted submissions, not per-patient risk.

About liraglutide

Liraglutide is a medicine that helps lower blood sugar levels. It is used with diet and exercise to treat type 2 diabetes in adults and children 10 years and older.

Used for: Liraglutide helps manage blood sugar levels in people with type 2 diabetes. You should use it along with a healthy diet and regular exercise. It is for adults and children aged 10 and older.

3 GLP-1 Receptor Agonist peers (wide set)

Compare liraglutide vs dulaglutide side-by-side →

liraglutide vs dulaglutide & exenatide · FAERS reaction fields

FAERS top-reaction field "Blood Glucose Increased" shows the widest count spread between liraglutide and dulaglutide, exenatide, semaglutide in this extract (11,597-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect liraglutide dulaglutideexenatidesemaglutide
Nausea 7,005 9,986 12,040 10,666
Blood Glucose Increased 3,875 9,762 15,472 2,752
Vomiting 3,364 5,413 4,345 6,913
Diarrhoea 3,263 5,737 2,742 6,093
Pancreatitis 2,315 - 2,012 -
Weight Decreased 2,076 3,349 12,125 3,931
Decreased Appetite 2,066 3,153 5,643 4,428
Headache 1,988 - 2,086 3,156

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

liraglutide shortage vs GLP-1 Receptor Agonist peer index

Shortage status

FDA shortage listing is active for liraglutide (status: Current). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for liraglutide while peers remain indexed?
Yes - liraglutide matched an active FDA shortage listing (Current) while 3 other GLP-1 Receptor Agonist SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full liraglutide profile →

Field note for liraglutide: see also the generic vs brand label guide when reading Victoza SPL strings.